In Brief: Biex SalEst test
This article was originally published in The Gray Sheet
Biex SalEst test: FDA grants expedited review to a premarket approval application submitted in July for the test system, which is intended to identify women at risk for preterm labor and delivery, the firm states. The test is designed to predict the risk of preterm delivery via measurement of salivary estriol (E3), an estrogen hormone produced by the placenta and the fetoplacental unit after the ninth week of gestation ("The Gray Sheet" Sept. 16, 1996, I&W-7)...
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.